Comparison of clinical progress between the 1-month and 12-month groups of double antiplatelet therapy in patients undergoing percutaneous coronary intervention with Genoss®DES: prospective, multicenter, randomized, open label clinical trial
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0006006
- Lead Sponsor
- The Catholic University of Korea, Seoul St. Mary's Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 2186
1)Subject must be = 19 years.
2)Patients who underwent percutaneous coronary intervention with Genoss®DES
3)Patients who assigned informed consents and actively participating in this study
1)The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Sirolimus, and Contrast media (Patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine [e.g. rash] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled.)
2)Noncardiac comorbid conditions are present with life expectancy <1 year
3)Patients who have visited the hospital in a cardiogenic shock and are expected to be less likely to survive from the site investigator's medical judgment
4)If the investigator determines that it is not suitable for this clinical trial or may increase the risk associated with participating in this test
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method a composite of Cardiovascular death, Myocardial Infarction, ischemic or hemorrhagic stroke, definite Stent Thrombosis, or Bleeding Academic Research Consortium, BARC) type 3 or 5 bleeding
- Secondary Outcome Measures
Name Time Method a composite of Cardiovascular death, Myocardial Infarction, ischemic or hemorrhagic stroke, definite Stent Thrombosis, or Bleeding Academic Research Consortium, BARC) type 3 or 5 bleeding;Cardiovascular end point (a composite of Cardiovascular death, Myocardial Infarction, ischemic or hemorrhagic stroke, definite Stent Thrombosis);Bleeding Academic Research Consortium, BARC) type 3 or 5 bleeding;all cause death;cardiac death;all myocardial infarction;ischemic or hemorrhagic stroke;definite or probable stent thrombosis;any revascularization;ischemia-driven target lesion revascularization;target vessel revascularization;Bleeding Academic Research Consortium) type 2 to 5 bleeding.;(Bleeding Academic Research Consortium) type 3, 4, and 5 bleeding;the occurrence of a composite net clinical effects (major adverse cardiac and cerebrovascular events or serious bleeding) and any damage or complications that may have been associated with the procedure